L1CAM-associated extracellular vesicles: A systematic review of nomenclature, sources, separation, and characterization

Dimitria E. Gomes1,2 | Kenneth W. Witwer2,3,4

1 Cornell University College of Veterinary Medicine, Ithaca, New York, USA
2 Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
3 Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
4 The Richman Family Precision Medicine Centre of Excellence in Alzheimer’s Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Correspondence
Kenneth W. Witwer, Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Email: kwitwer1@jhu.edu

Funding information
National Institute on Drug Abuse, Grant/Award Number: R01DA047807; National Institute of Mental Health, Grant/Award Number: R21/R33MH118164; National Institute of Allergy and Infectious Diseases, Grant/Award Number: R01AI144997; National Cancer Institute (NCI); Office of the Director, Grant/Award Number: UGCA241694; Michael J. Fox Foundation, Grant/Award Number: 00901821

Abstract
When released into biological fluids like blood or saliva, brain extracellular vesicles (EVs) might provide a window into otherwise inaccessible tissue, contributing useful biomarkers of neurodegenerative and other central nervous system (CNS) diseases. To enrich for brain EVs in the periphery, however, cell-specific EV surface markers are needed. The protein that has been used most frequently to obtain EVs of putative neuronal origin is the transmembrane L1 cell adhesion molecule (L1CAM/CD171). In this systematic review, we examine the existing literature on L1CAM and EVs, including investigations of both neurodegenerative disease and cancer through the lens of the minimal information for studies of EVs (MISEV), specifically in the domains of nomenclature usage, EV sources, and EV separation and characterization. Although numerous studies have reported L1CAM-associated biomarker signatures that correlate with disease, interpretation of these results is complicated since L1CAM expression is not restricted to neurons and is also upregulated during cancer progression. A recent study has suggested that L1CAM epitopes are present in biofluids mostly or entirely as cleaved, soluble protein. Our findings on practices and trends in L1CAM-mediated EV separation, enrichment, and characterization yield insights that may assist with interpreting results, evaluating rigor, and suggesting avenues for further exploration.

KEYWORDS
ectosomes, exosomes, extracellular vesicles, immunoaffinity, L1CAM, microvesicles, MISEV, neurons, systematic review

1 INTRODUCTION

Extracellular vesicles (EVs) are a heterogeneous group of membrane-bound particles that are released by all studied cell types (Cocozza, Grisard, Martin-Jaular, Mathieu, & Théry, 2020; Van Niel, D'Angelo, & Raposo, 2018; Yáñez-Mó et al., 2015; Yates et al., 2022). Most abundant in the 30–150 nm diameter range, EVs function in waste removal and cell-cell communication by transporting nucleic acids, lipids, proteins, and other molecules (Harding, Heuser, & Stahl, 1983; Johnstone, 1992; Mateescu et al., 2017; Russell et al., 2019). EVs are commonly classified by biogenesis into plasma membrane-origin ectosomes (or microvesicles) and endosome-origin exosomes, although physical separation of these different classes is difficult (Cocucci & Meldolesi, 2015; Lötvallet al., 2014; Meldolesi, 2021; Théry et al., 2018; Witwer & Théry, 2019). EVs have also been reported to cross bodily barriers such as the mammalian blood-brain barrier (Alvarez-Erviti et al., 2011; Dickens et al., 2017; Pulliam, Sun, Mustapić, Chawla, & Kapogiannis, 2019; Russell et al., 2019). Due to the relative clinical inaccessibility of the brain, diseases and conditions of the central nervous system (CNS), including neurodegenerative diseases such as Alzheimer’s and Parkinson’s, present diagnostic,
prognostic, and monitoring challenges for which EVs in biofluids are a potential solution (Campbell & Mocchetti, 2021; Coleman & Hill, 2015; Manu, Hohjoh, & Yamamura, 2021; Thompson et al., 2016; Upadhya & Shetty, 2021; Vandendriessche, Bruggeman, Van Cauwenberghe, & Vandenbergroucke, 2020) as a kind of ‘liquid biopsy’: if displaying markers of the cell of origin, EVs and their cargo of proteins, nucleic acids, and more can theoretically be traced back to the parent cells and can serve as indicators of cell and tissue health (Pulliam et al., 2019; Shankar, Balaj, Stott, Nahed, & Carter, 2017; Vassileff, Cheng, & Hill, 2020). However, realizing the promise of EVs requires highly specific and abundant surface markers that can be used as molecular handles to separate target EVs from the high background of EVs from other cells in biofluids like blood (Thompson et al., 2016).

To date, the L1 cell adhesion molecule (LICAM, also known as CD171 or simply L1) has been most frequently used to obtain materials of putative CNS neuronal origin for biomarker discovery and validation studies (Pulliam et al., 2019). LICAM is a member of the L1 family of adhesion proteins. Usually, expressed as a single-pass transmembrane protein, LICAM contains immunoglobulin domains and fibronectin-like repeat domains in an extracellular, N-terminal portion, while a cytoplasmic C-terminal tail participates in signalling within the cell (Samatov, Wicklein, & Tonevitsky, 2016). Splice forms lacking the transmembrane domain have also been described (Angiolini et al., 2019). Various functions in neuronal migration and differentiation have been ascribed to the adhesive and cell transduction properties of the protein (Maness & Schachner, 2007). In investigations of LICAM-positive EVs, antibodies to LICAM are typically mixed with whole or partly processed biofluids, and materials attached to the antibodies are enriched and molecularly profiled. This approach has been used to propose molecular profiles associated with Alzheimer’s disease, Parkinson’s disease, mild cognitive impairment, HIV-associated neurocognitive disorders, traumatic brain injury, and more.

However, the utility of LICAM as a marker of brain neuronal EVs has also been questioned for several reasons (Hill, 2019; Norman et al., 2021). First, LICAM expression is not restricted to CNS neurons (Hill, 2019). LICAM was discovered in neurons (Faissner, Kruse, Nieke, & Schachner, 1984), but it may also be expressed by oligodendrocytes in the brain. In the periphery, according to protein and gene expression data, a wide variety of cells, including peripheral neurons and Schwann cells; melanocytes; immune cells such as T cells, B cells, and monocytes; and certain epithelial and endothelial cells; may express LICAM. The protein is produced in several types of cancer, with higher levels indicating advanced disease and poor prognosis (Altevogt et al., 2020; Colombo & Meldolesi, 2015; Fogel et al., 2003; Gavert, Ben-Shmuel, Raveh, & Ben-Ze’ev, 2008). Indeed, the earliest studies of EV LICAM were in the context of cancer (Gutwein et al., 2003; Gutwein et al., 2005). Second, the membrane association of the LICAM extracellular portion may be transient since the LICAM ectodomain is susceptible to proteolysis (Gutwein et al., 2000; Li & Galileo, 2010; Linneberg, Toft, Kjaer-Sorensen, & Laursen, 2019; Sugawa, Ono, Yasui, Kishi, & Tsumori, 1997; Yang et al., 2009). Recently, Norman et al. reported that LICAM epitopes are present in blood and cerebrospinal fluid mostly or entirely as cleaved, soluble protein, not as EV transmembrane molecules (Norman et al., 2021). Third, the specificity of at least one LICAM antibody is unclear. Norman et al. reported cross-reactivity of the antibody with alpha-synuclein, a protein commonly assayed after LICAM immunoprecipitation (IP), potentially explaining the positive biomarker results of some studies (Norman et al., 2021). Fourth, the widely held and oft-repeated assumption that EVs easily cross the blood-brain barrier is still supported mostly by indirect evidence (Verweij et al., 2021).

In this review, we assessed the reporting within the EV LICAM literature through the lens of the minimal information for studies of EVs (MISEV) (Théry et al., 2018; Witwer et al., 2021), specifically in the four domains of nomenclature usage, EV sources, EV separation, and EV characterization. We sought to trace the ‘interpretation landscape’ around published LICAM EV studies. For each study, we asked several questions. What types of EVs were studied (or presumed to be studied), and how were they defined? What sources of EVs were used? What were the methods of EVs separation and/or concentration? Which anti-LICAM antibodies were used? How were EVs characterized? Which EV and non-EV markers (enriched/depleted), if any, were examined? What components of EVs were profiled? The overall goal was to understand what interpretations of EV LICAM affinity studies can be admitted or excluded, and what might be done to enhance future studies.

## RESULTS AND METHODS

### 2.1 Literature search and selection

A literature search was performed using the three databases PubMed, Web of Science, and Scopus. The following keywords/MeSH terms and operators were used: (LICAM OR ‘L1 cell adhesion molecule’) AND (exosome OR exosomes OR ‘extracellular vesicle’ OR ‘extracellular vesicles’ OR ectosome OR ectosomes OR microvesicle OR microvesicles). Only English-language studies were included. All studies published from the start of each database until end of July, 2021 were included. Manuscripts found in two or more databases were included only once, for a total of 59 publications (Figure 1). These were manually curated to select only those with primary research data that reported on putatively LICAM-associated EVs. Three review publications (without primary data) were removed. Five studies that did not specifically combine LICAM and EVs were also removed. A total of 51 articles thus satisfied all criteria (see Figure 1 and list of papers in Table S1) (Anastasi et al., 2021; Athauda et al., 2019; Bhargava et al., 2021; Cha et al., 2019; Chawla et al., 2019; Cressatti et al., 2021; Dagur et al., 2020; Eitan et al., 2017; Fauré et al., 2006; Fu, Jiang, Tofaris,
FIGURE 1 Flow diagram of literature search strategy and inclusion and exclusion criteria

& Davis, 2020; Goetzl et al., 2019; Goetzl et al., 2015; Goetzl, Peltz, Mustapic, Kapogiannis, & Yaffe, 2020; Gomes et al., 2015; Gu et al., 2020; Gutwein et al., 2003; Gutwein et al., 2005; Herrero et al., 2019; Jiang et al., 2020; Jiang et al., 2021; Keller et al., 2009; Kodidela et al., 2020; Kumar et al., 2021; Mansur et al., 2021; Mullins, Mustapic, Goetzl, & Kapogiannis, 2017; Nasca et al., 2021; Nogueras-Ortiz et al., 2020; Norman et al., 2021; Pace, Dutt, & Galileo, 2019; Patterson, Deep, & Brinkley, 2018; Peltz et al., 2020; Pulliam, Liston, Sun, & Narvid, 2020; Rani et al., 2019; Shi et al., 2016; Shi et al., 2019; Si et al., 2019; Stoeck et al., 2006; Suire et al., 2017; Sun, Dalvi, Abadjian, Tang, & Pulliam, 2017; Sun, Fernandes, & Pulliam, 2019; Trnka, Ivanova, Hiatt, & Matsell, 2012; Walker et al., 2021; Webber et al., 2014; Winston et al., 2019; Winston et al., 2016; Winston, Goetzl, Baker, Vitiello, & Rissman, 2018; Yang et al., 2009; Yang et al., 2011; Yuyama et al., 2019; Zhao et al., 2020; Zou et al., 2020).

2.2 Types of EVs and nomenclature

The first MISEV category is nomenclature. ISEV recommends the term ‘extracellular vesicle’ unless the biogenetic origin of EVs can be established (Lötvall et al., 2014; Théry et al., 2018): plasma membrane origin for ectosomes (or ‘microvesicles’) and endosomal origin for exosomes. The MISEV2018 consensus guidelines further define EV as the generic term for particles released from the cell, delimited by a phospholipid bilayer, and without a functional nucleus, and suggest that the term ‘EV’ can be used as a scaffold for further descriptors (if clearly defined), such as size, source, surface markers, and conditions of production (Théry et al., 2018). In practice, terms have been used inconsistently and sometimes without clear definition in the literature (Witwer & Théry, 2019). Beyond the consensus, biogenesis-based definition, the term ‘exosome’ in particular has been used inconsistently to describe any EV, an EV within an arbitrary size range, an EV population positive for one or more tetraspanins or other EV markers, or the products of specific separation/concentration methods, such as ultracentrifugation or PEG precipitation. Since physical and biochemical characteristics of exosomes overlap substantially or entirely with those of other EV classes, most studies that claim to have studied exosomes have instead included a mixture of various EVs and often non-EV extracellular particles (EPs).

In the LICAM literature we analysed, we identified the primary term(s) used to describe EVs. In most papers, one term was used exclusively or predominantly, but several articles used terms interchangeably, usually ‘EV’ and ‘exosome.’ 32 articles used the term ‘exosome’ or a modified term like ‘NDE’ for ‘neuron-derived exosome’ (Table 1). 20 used ‘EV’ or modified terms (Table 1). Other terms, all used before MISEV2014 appeared, were ‘membrane vesicle’, ‘microvesicle’, and ‘exosome-like vesicle’ (Table 1). In several papers, the term ‘vesicle’ was used loosely in the text to refer to one or more subpopulations, but we did not track this informal usage. The term ‘EV’ was first mentioned in LICAM studies in 2014 and came into primary usage in a publication in 2015. Since 2018, and with a sharp spike in the number of papers per year, there appears to be a trend toward more use of ‘EV’ and diminished use of ‘exosome’ (Figure 2a).
TABLE 1  Nomenclature in EV L1CAM studies

| Term     | Number | References                        |
|----------|--------|-----------------------------------|
| EV       | 20     | 28,44,46-48,51,52,54-56,65,66,70,71,75,77,87,88,90 |
| Exosome  | 32     | 36,39,45,49,50,52,53,55,57-65,69,72-74,76,79-86,89 |
| Other    | 4      | 35,76,83,86                        |

FIGURE 2  EV nomenclature used in studies of L1CAM and EVs. (a) EV nomenclature by year of publication. *: 2021 articles were analysed only through end of July. (b) Definition of ‘exosome’ for the 32 papers in which the term ‘exosome’ was used primarily. Percentages do not add up to 100% because some papers included multiple definitions.

Of 32 papers that reported primarily on ‘exosomes’ or that used the term interchangeably with ‘EVs,’ 14 defined exosomes canonically by endosomal origin, whether or not this origin was investigated or established (Figure 2b). Several articles used diameter/size as a stand-alone or additional exosome-defining characteristic, including at least seven that provided specific diameter ranges (Figure 2b)—20–100 nm, 30–150 nm, 40–100 nm, 40–120 nm, 40–140 nm—and others that described exosomes simply as ‘small.’ Only rarely did the up-front exosome definition mention a certain marker, such as CD63, although more papers used markers such as CD63, CD81, TSG101, and Alix to characterize EVs (see below). In contrast, 18 articles did not define ‘exosome’ clearly, gave two or more seemingly contradictory definitions (likely reflecting general confusion in the field at the time of writing), or used terms interchangeably (Figure 2b). At least six defined/used ‘exosome’ as synonymous with ‘EV.’ Several papers gave two or more seemingly contradictory definitions of exosomes. One paper used ‘exosomes’ in the title and abstract, then switched to EV throughout methods and results (Athauda et al., 2019), while another used EV throughout, except for a methods section that referred to exosomes (Pulliam et al., 2020).

3 SOURCES OF EVS FOR LICAM STUDIES

The second MISEV2018 category covers sources of EVs and preprocessing variables (Théry et al., 2018). We did not compare the reporting of preprocessing variables due to a general lack of information and standardized reporting on these variables in most studies. There is thus considerable room for improvement in the reporting of preprocessing variables [a general issue in
TABLE 2 Sources of EVs in LICAM EV studies

| Source                          | n (of 51) | References                               |
|---------------------------------|-----------|------------------------------------------|
| Blood products (plasma, serum)  | 40        | 44,53,55,58,64-66,74,83,89               |
| Serum                           | 10        | 44,53,55,58,64-66,74,83,89               |
| Plasma                          | 31        | 28,44-52,53,56,57,59,61,63,67-73,75,76,78,79,85,87-89 |
| Blood + Other                   | 10        |                                         |
| Cell culture-conditioned medium | 14        | 35,39,49,56,57,59,62,85,77,80-82-84,86   |
| Brain tissue                    | 2         | 55,58                                    |
| CSF                             | 2         | 28,44                                    |
| Urine                           | 2         | 44,81                                    |
| Ascites                         | 2         | 36,83                                    |
| Saliva                          | 2         | 44,60                                    |

TABLE 3 Separation and concentration methods

| Separation/concentration method  | n (of 51) | References                               |
|----------------------------------|-----------|------------------------------------------|
| Affinity (immunoprecipitation/capture, FACS) | 35        | 28,44-51,53-56,59,61,63-75,78,79,85,87,88,90 |
| PEG or PEG-based kit            | 30 (26 combining PEG and IP) | 44-52,56,57,5-61,63,64-65-73,75,78,87,88,89 |
| Differential ultracentrifugation | 17        | 28,35,36,39,55,57,58,62,69,76,77,80-84,86 |
| Density gradient or cushion ultracentrifugation | 9         | 28,35,36,55,58,80,83,84,86               |
| Size exclusion chromatography    | 3         | 28,57,85                                 |

the EV field, not just for LICAM studies (Clayton et al., 2019; Erdbrügger et al., 2021; Royo, Théry, Falcón-Pérez, Nieuwland, & Witwer, 2020; Witwer et al., 2013) and little information on how these variables might affect the presence or detection of EV-associated LICAM in specific sample types. As for sources of EVs, approximately 96% (n = 49) of the 51 articles used human patient or human-origin cells. Four used samples from animal models: nonhuman primate (Kumar et al., 2021), rat (Dagur et al., 2020), and mouse (Shi et al., 2014; Yuyama et al., 2019). Both articles that used mouse models also used human samples (serum). Blood products (n = 40: serum, plasma, or both) were the most common EV source, consistent with recent field-wide surveys (Gardiner et al., 2016; Nieuwland, Falcón-Pérez, Théry, & Witwer, 2020; Royo et al., 2020) and with the ease of collection of blood and perceived potential as a ‘liquid biopsy’ (Table 2) (Clayton et al., 2018). Plasma (n = 31) was used more frequently than serum (n = 10). Of the 40 articles that used blood derivatives, several used other fluids/tissue, such as CSF (Cressatti et al., 2021; Norman et al., 2021), brain tissue (Dagur et al., 2020; Yuyama et al., 2019), urine (Cressatti et al., 2021), ascites fluid (Keller et al., 2009), and saliva (Cressatti et al., 2021) (Table 2). One article each used saliva (Rani et al., 2019), urine (Trnka et al., 2012), and ascites fluid (Gutwein et al., 2005) as the sole EV source (Table 2). Human cell culture-conditioned medium (CCM) was a source of EVs in 14 articles (Table 2). Use of CCM in LICAM EV studies has become less prevalent over time: in eight of 12 studies published prior to 2016, but in only six of 37 from 2016 and later.

4 SEPARATION AND CONCENTRATION OF LICAM-ASSOCIATED EVS

The third MISEV domain is separation and concentration of EVs (Théry et al., 2018). Each separation method discriminates by affinity, size, or density, or some combination thereof, and falls at a different place in the EV specificity/recovery matrix (Cocozza et al., 2020; Théry et al., 2018). Multiple methods may be needed to achieve a desired purity or recovery outcome. Methods that reduce sample volume, recovering most EVs without substantial increases in EV purity, might be considered ‘concentration’ rather than separation methods. Foremost in this category is precipitation or salting-out, for example, by polyethylene glycol (PEG) or ammonium sulphate. Commercial kits that are advertised as ‘exosome isolation’ reagents are mostly based on this approach. In contrast, affinity capture methods may achieve high specificity but low yield, depending on the antigen that is captured. In LICAM EV studies, a common workflow first concentrates material by PEG precipitation and then uses antibodies to capture putative LICAM-positive material from the precipitated pellet (Table 3, Figure 3).

Distribution of concentration/separation methods in n = 51 publications. Several studies used multiple workflows. Some combined more than one method in at least one workflow (n = 39), and these were counted in all respective categories.
FACS = fluorescence-activated cell sorting; PEG = polyethylene glycol. Ultrafiltration of various types was also an occasional component of EV workflows (not shown).

4.1 Precipitation

The second most commonly used separation/concentration method in the literature we surveyed was polymer precipitation (Table 3, Figure 3). Polyethylene glycol-based precipitation is the presumed basis of numerous commercial kits that are advertised as specific for ‘exosome isolation.’ This approach is, however, not specific for exosomes or EVs, and the precipitate from many EV sources will be predominantly nonvesicular. As such, the method might be best referred to as concentration. PEG or presumed PEG-based kits were used in 30 of the 51 studies we reviewed, in at least three as a stand-alone method (Table 2, Figure 3). For 26 of the 35 studies involving L1CAM immunocapture, an initial PEG concentration was followed by immunocapture. This combination was thus the most common workflow overall. Of the 30 PEG/precipitation protocols, one used a homemade PEG formulation, 27 used kits from System Biosciences, two used a kit from Thermo Fisher, and one protocol each used materials from Nasabiotec and Cell Guidance Systems. The total ‘n’ is greater than the number of articles because of a comparison of multiple kits. We note that the Cell Guidance Systems kit combines PEG and SEC. The SEC step may be important for some downstream assays by increasing purity and removing PEG.

4.2 Size- and density-based separation

Differential ultracentrifugation, historically the most widely used EV separation technique (Gardiner et al., 2016; Royo et al., 2020), was employed in at least 17 studies. We did not count a medium-speed, preclearing step prior to PEG precipitation as differential ultracentrifugation. Ten studies used density gradients ultracentrifugation or cushion ultracentrifugation. Three used size-exclusion chromatography, and at least two used ultrafiltration (Table 3, Figure 3).

4.3 Affinity-based separation

L1CAM affinity capture techniques were the most common method of EV separation in the L1CAM literature (n = 35; Table 3, Figure 3). Ectodomains of proteins embedded in the EV lipid bilayer (such as L1CAM) can be recognized by affinity reagents—most commonly, antibodies—and used to select EVs displaying that marker. Antibodies are typically affixed to a surface, such as magnetic beads, nonmagnetic beads, some other matrix material, or a plate, to facilitate separation of bound from unbound material using, for example, a magnet, centrifugation, fluorescence-activated cell sorting (to sort EV-binding beads), or plate washing. Captured and purified EVs can then be eluted for subsequent characterization and functional studies or solubilized directly on the capture surface for certain assays.

Of the 35 papers that clearly specified an L1CAM capture strategy, at least 19 used the 5G3 clone that recognizes an N-terminal portion of the L1 ectodomain (Ig-like domains), and one used another clone that binds a similar region (Table 4, Figure 4). At least seven papers did not specify the clone, but most or all of these likely used the 5G3 clone based on citation and authorship. Seven used the UJ127 clone that recognizes an ectodomain epitope closer to the plasma membrane (in the fibronectin type III domains; Table 4, Figure 4). One paper appeared to imply that affinity capture was done but gave no related methods (Peltz et al., 2020). Twenty-five of 35 papers did not specify the catalogue number of the antibody. Although the identity of the clone is most crucial, catalogue number can also be important information, since different formulations are available.
TABLE 4  Anti-L1CAM antibodies used for reported capture of EVs

| LICAM antibody clone | n (of 35) | Epitope                                     | Example references |
|----------------------|-----------|---------------------------------------------|--------------------|
| 5G3                  | 19        | Ectodomain, immunoglobulin-like domains 1 to 2; near N-terminus | 44,45,49,51,59,61,66-73,78,85,87-89 |
| EPR2324I-224         | 1         | Similar epitope to 5G3                      | 28                 |
| UJ127 (UJ127.11)     | 7         | Ectodomain, fibronectin type III repeats    | 53,64,74,76,79,85,90 |
| C2C (or 2C2)         | 1         | Intracellular, C-terminus; cross-reactive with CHL1 | 54                 |
| LS-C470565           | 1         | Intracellular, C-terminus                   | 55                 |
| Unspecified          | 7         | N/A                                         | 46-48,50,56,63,65  |

FIGURE 4  Cartoon of LICAM’s molecular organization relative to the cell membrane. -NH2 = amino (N) terminus; -COOH = carboxy (C) terminus

for some antibodies, and there may be manufacturer-specific differences. Interestingly, two papers reported immunocapture of LICAM-positive EVs using antibodies C2C (2C2) (Zou et al., 2020) and LS-C470565 (Table 4, Figure 4) (Dagur et al., 2020). These antibodies reportedly recognize epitopes at the C-terminal end of LICAM and should thus be intracellular or, for an EV, intraluminal.
**Use of physical characterization techniques**

| Technique                                      | n (of 51) | References |
|-----------------------------------------------|-----------|------------|
| Optical/Electrical Methods (OEM): RPS, NTA, DLS | 22        | 44-49,52,54,55,57,60,63,66,70,72,75-77,80,85,87,88 |
| Non-Optical Microscopy (NOM): TEM, SEM, AFM    | 19        | 28,35,46,49,52-55,57,58,62,64,75,76,79,82,84,85,90 |
| Multiple                                       | 10        | 46,49,52,54,55,57,75-77,85,90 |
| None (in several cases, techniques were mentioned but results not reported) | 19        | 36,39,50,51,56,59,61,65,67-69,71,73,74,78,81,83,86,89 |

## 5 CHARACTERIZATION OF LICAM-ASSOCIATED EVS

Following separation, EV characterization is recommended as the fourth MISEV domain (Théry et al., 2018). Characterization is needed to identify what is present and enriched—and, ideally, what is not present or is depleted—in the EV preparation. Per MISEV2018, characterization should include physical characterization, such as particle size profiling, particle counting, and single-particle visualization, and molecular assessment of both positive (enriched) EV markers and negative (or depleted) markers of potentially coseparated non-EV components. Depending on EV source, the latter may include materials from dead cells, lipoprotein particles, and protein aggregates that overlap in size and/or density with EVs (Théry et al., 2018).

### 5.1 Physical characterization

For the purposes of this study, we classified physical characterization methods into two broad categories: ‘optical/electrical methods’ (OEM) and ‘nonoptical microscopy methods’ (NOM). The former include nanoparticle tracking analysis, NTA, resistive pulse sensing (RPS), and dynamic light scattering (DLS). These methods can be used to count particles within certain size ranges and, to varying degrees, to determine particle size or features of size distribution. However, they do not on their own discriminate between EVs and non-EV particles. In contrast, the various forms of electron microscopy (EM) and atomic force microscopy (AFM) can at least theoretically identify EV-specific morphology or other properties. Using multiple complementary physical characterization methods can be helpful to obtain more information about an EV preparation (Arab et al., 2021; Théry et al., 2018; Vogel et al., 2021) (cite).

Of the 51 LICAM articles surveyed, 19 (37%) presented no physical characterization results (Table 5, Figure 5a). In at least three of these, physical methods were mentioned, but no data were shown or described. Twenty-two studies presented OEM data (Table 5, Figure 5a). Of these, 21 used NTA either as the sole physical characterization method (Meldolesi, 2021) or in combination with other methods. DLS was used by two and RPS by one. Ten studies reported data from more than one physical characterization technique (whether OEM or NOM; Table 5, Figure 5a). Most studies did not provide sufficient information to assess variability across samples, showing, for example, only one NTA profile and/or one electron micrograph.

Demarcating the literature by the appearance of MISEV2018, the percentage of papers with no physical characterization was at 50% both pre-MISEV2014 (five papers, n = 10) and between MISEV2014 and MISEV2018 (five papers, n = 10) but fell to 29% post-MISEV2018 (nine papers, n = 31; Figure 5a). During these periods, the proportion of articles with multiple physical characterization methods rose from 0% (pre-MISEV2014) to 20% (from MISEV2014-MISEV2018, n = 2), and finally to 26% (post-MISEV2018, n = 8) (Figure 5a).

### 5.2 EV cargo analysis methods

EV markers analysed in the LICAM EV literature were predominantly proteins. Fort nine of 51 articles (96%) used some form of EV protein analysis. To detect specific proteins (Figure 5b), researchers used Western blotting (n = 31, ~61% of total), regular or multiplexed ELISA (n = 27, 53%), single-molecule analysis (Simoa, an ultrasensitive ELISA; n = 4, ~8%), and flow cytometry (n = 4, ~8%). 24 studies used more than one method (~47%). Broader protein profiling was done by mass spectrometry in nine studies (~18%). Other protein detection technologies included immunogold EM, antibody arrays, aptamer affinity, and proximity extension assays. Acetylcholinesterase (AChE) activity detection was used in one study (Nasca et al., 2021), and although AChE is not a generic marker of EVs (Liao et al., 2019), it is possible that neuronal EVs might contain this enzyme; this possibility could be worth further investigation. In contrast with protein, nucleic acids were not widely investigated. Only three papers reported profiling of EV RNA and/or qPCR of individual RNAs (see below).
GOMES and WITWER

FIGURE 5 Characterization of EVs. (a). Timeline of usage of physical characterization techniques. OEM = optical/electrical methods: resistive pulse sensing (RPS), nanoparticle tracking analysis (NTA), dynamic light scattering (DLS); NOM = nonoptical microscopy: transmission electron microscopy (TEM), scanning electron microscopy (SEM), atomic force microscopy (AFM). Please note that other methods could be included in these categories, but this list is limited to techniques used in the studies selected for analysis. (b). Methods used for identification of individual EV proteins. WB = Western blot; ELISA = enzyme-linked immunosorbent assay; MassSpec = mass spectrometry; ‘Other’ techniques included dot blots/antibody arrays

5.3 Identities of individually targeted molecules

L1CAM and generic EV markers

As stated, proteins were the most frequently targeted molecular class. Naturally for the focus of these studies, L1CAM was among the most commonly probed targets (n = 22 studies, 43%; Figure 6), and usually detected by Western blot. Antibodies commonly used for L1CAM detection are listed in Table S2. For selected examples (nonexhaustive) of other proteins and the techniques used to detect them, see Table S3. As generic surface markers of EVs, the tetraspanins CD9 (n = 13), CD63 (n = 14), and CD81 (n = 17) were commonly used (Figure 6). Internal EV proteins were also probed for in some studies, including Alix (n = 14), TSG101 (n = 11), and syntenin (n = 2) (Figure 6). At least 22 studies specifically measured generic transmembrane and internal proteins, as now recommended by MISEV, including 40% of articles prior to MISEV2014, 20% between MISEV2014 and 2018, and almost 52% of those after 2018.

Negative/depleted non-EV markers

We were able to locate only ten articles in which data for a specifically probed negative/depleted marker of non-EV material was shown, and all but two of them were published in 2019 or later. Of these ten, four probed for the Golgi marker GMI30 (GOLGA2) and five for calnexin, an endoplasmic reticulum marker. These proteins are presumed to be depleted in EVs compared with source cells and may indicate excessive cell death and EV-like artifacts in cell culture. We were especially impressed with one study in cell
culture that measured markers from multiple cellular compartments in EVs and other fractions (Gomes et al., 2015). However, whether these ‘deep cellular’ markers adequately monitor coisolates from biological fluids is perhaps less clear. In this light, one article checked albumin levels (Norman et al., 2021), which may be indicative of protein contamination in biofluid sources including blood, and another study checked Apo-A1 (Nogueras-Ortiz et al., 2020), the major protein of high-density lipoprotein particles (HDL). We refer here only to specifically probed markers. Potentially, information about depleted markers could also be gathered from proteomics data in the cases of studies that reported mass spectrometry results.

In most of the studies analysed here, putative EV cargo molecules were specifically measured or broadly profiled to assess biomarker potential and/or identify possible disease mechanisms, mostly for CNS disorders. We did not design this study to evaluate the strength of the evidence for these measurements and profiling studies and instead focused on the basic MISEV2018 recommendations for EV characterization. However, we can make several observations. ELISAs, including multiplexed ELISAs, as well as single-molecule analysis (SIMOA, a kind of ultrasensitive ELISA), were commonly used to quantitate known CNS disease markers such as alpha synuclein, amyloid beta, tau (including phosphorylated forms), neurofilament light (NfL), and neurogranin (NRGN), among others, in precipitated and/or selected material. Proximity ligation assays and mass spectrometry were also used. Targeted detection of betaIII-tubulin was done in one study to interrogate the neuronal origin of selected material (Zou et al., 2020). In another study, NCAM was found in L1CAM-selected material, although NCAM expression is also not restricted to neurons. These results may be interpreted as evidence that L1CAM reagents select for neuronal EVs. On the other hand, additional controls may be needed to bolster these conclusions. The study that measured betaIII-tubulin immunoselected using an antibody raised to a luminal L1CAM epitope (Zou et al., 2020), which may complicate interpretation. Another study detected glial fibrillary acidic protein (GFAP) in putative L1CAM+ material (Nogueras-Ortiz et al., 2020), an unexpected result. Finally, a proteomics study of L1CAM capture identified two proteins that were significantly enriched in brain, but also found significant enrichment of components of common contaminants of EV preparations, including circulating IgG complexes, HDL, very low-density lipoproteins (VLDL) and chylomicrons (Winston et al., 2016).

RNA analytes

Of the three publications that examined RNA, in one study, several miRNAs were chosen based upon expression in brain tissue. miRs-212, -132, -566, -182-5p, and -1304-5p were then quantitated by qPCR, with normalization to miR-16 (Cha et al., 2019). Interestingly, in this study, miR-9 and miR-451a were also assessed, and the authors concluded that miR-9, a CNS-enriched miRNA, was also enriched in the L1CAM-precipitated material (Cha et al., 2019). Another study amplified miR-155 by qPCR, with normalization to GAPDH mRNA (Anastasi et al., 2021). Finally, one study examined long noncoding RNA by hybridization microarray, followed by validation of one lncRNA by qPCR, with normalization to GAPDH (Zou et al., 2020).

6 CONCLUSIONS

The findings of this review suggest several opportunities for progress in the study of L1CAM and EVs, as seen through the lens of MISEV (Théry et al., 2018). First, EV nomenclature remains somewhat confused, especially in that ‘exosome’ and ‘EV’ have often been used interchangeably despite a lack of investigation of the ratio of EVs with endosomal versus plasma membrane origin.
Following consensus nomenclature may enhance clarity: using EV generally and reserving 'exosome' and 'ectosome/microvesicle' for particles with proven biogenesis.

A second opportunity is to seek better understanding of the influence of sample characteristics and preanalytical variables (such as sample collection, processing, and storage/handling) as well as EV separation steps on the presence and detectability of EV-associated LICAM in EV preparations. Here and in later characterization steps, normalization is of particular interest. In most of the studies we reviewed, no normalization was done prior to measurements beyond equalizing starting volumes and/or dilutions. Also, since most of the recent LICAM EV literature is focused on biomarker development for CNS diseases and injuries, it is interesting to note that LICAM upregulation in several cancers has also been well established (Altevogt et al., 2020; Colombo & Meldolesi, 2015; Fogel et al., 2003; Gavert et al., 2008). It might therefore be important in future studies to report on and control for cancer burden in patient and control populations. Similarly, instructive will be knowing the extent to which preanalytical variables might affect artificial detection of non-membrane-integral proteins including cleaved LICAM itself.

Although we could not conduct a full analysis of preanalytical variables here, as they were generally not reported or inconsistently reported, an example of a potentially large influence of a preanalytical variable on LICAM detection is thrombin-mediated preclearing of fibrinogen/fibrin from plasma. By aggregation and conglomeration with other factors, fibrinogen is thought to affect plasma EV separation and characterization (Onodi et al., 2018), and this influence could be especially important for concentration methods. At least one precipitation kit manufacturer recommends and provides reagents for a thrombin pretreatment. However, of 26 articles that used PEG or PEG-based kits to precipitate particles from plasma, only eight specifically indicated thrombin treatment. Enhancing understanding and reporting of such variables would boost reproducibility and comparison between studies.

The MISEV domain of characterization provides additional opportunities for progress (Théry et al., 2018). Overall, in the current LICAM EV literature, the vesicular nature of separated particle populations has not been well supported by physical characterization, with almost 40% of articles reporting no physical characterization and others relying on techniques that do not detect EVs specifically. To be sure, some of these articles use the same methodology as previously published papers, and perhaps the authors felt that it was no longer necessary to perform characterization for an established method.

EV-enriched and -depleted marker characterization has also been limited. In some studies, LICAM itself was used as the only marker for EV characterization after an LICAM IP, an approach that cannot rule out artifacts of binding or aggregation. The presence of non-EV particles in EV preparations was only rarely evaluated. In most cases, only one cellular depleted marker was assessed. Although this may be appropriate for cell culture experiments, complex EV sources such as blood were used in most investigations. Importantly, several studies [e.g., (Anastasi et al., 2021; Peltz et al., 2020)] found evidence that non-neuronal materials were present in LICAM-precipitated material, including broad lipoprotein and free protein contamination (Anastasi et al., 2021). It is thus difficult to assess how non-EV particles and associated molecules might have contributed to the results of previous studies of LICAM+ EVs. Investigations with additional controls may be needed to understand these contributions.

However, improvements in characterization and reporting will go only so far with bulk assays. For example, detection of both LICAM and, say, CD81 in an EV population does not necessarily mean presence on the same particle. Similarly, finding LICAM and NCAM or NFL in the same population does not necessarily prove colocalization at the particle level. Ultimately, single-particle, multimarker studies will be needed to establish if LICAM is truly integral to neuron-derived EVs, tightly associated, or simply a contaminant of EV preparations.

With a single protein, LICAM, at the centre of all studies we examined, affinity reagents for that protein are naturally crucial to rigor and reproducibility, as well as increased vigilance for the possibility that antibodies to LICAM have nonspecific binding or capture soluble protein and associated material rather than EVs. Based on our observations, there is an opportunity for more transparency on which antibodies and formulations are used. Also, important is knowing which epitope each antibody recognizes and choosing reagents for different purposes based on this binding. For example, after an extracellular domain of LICAM is used for immunocapture, it might be useful to probe with an antibody to a cytoplasmic C-terminal domain to show that full-length LICAM is present and presumably captured. Similarly, antibodies to an EV-internal domain could be used as controls. Unexpectedly, internal epitopes were used for capture of putatively LICAM+ EVs in at least two studies (Daguer et al., 2020; Zou et al., 2020). How these epitopes would permit capture of intact EVs is unclear. Possibly, these antibodies might capture damaged EVs or cellular membrane fragments that form particles with ‘flipped’ membrane topology. In any case, understanding more about the nonspecific binding of anti-LICAM antibodies will be valuable.

We would like to conclude with some general remarks about strengths and weaknesses of this study and its findings. It is possible that our literature search may have missed important publications. A systematic review is also only as strong as the analysis and the individuals who contributed to it. With only two authors, our study may be considered weaker than studies with larger numbers of authors. However, we feel that the general conclusions would remain even if several publications or data points were missed. We would furthermore like to note that the need for more detailed method reporting or clearer use of nomenclature is in no way specific to the LICAM EV literature and is instead a general opportunity for improvement (Van Deun et al., 2017). Our findings are also not a criticism of any particular study or group. Although a general lack of EV characterization may cast doubt on some interpretations, our study does not cast doubt on other aspects of published findings. Especially for the majority of LICAM EV studies that focus on biomarkers of CNS disease, we must remember that a reproducible biomarker that
is captured by an anti-LiCAM antibody is still a reproducible biomarker. This is true even if LiCAM is not integral to EVs; even if the captured LiCAM did not come from a neuron; and even if the binding is to something other than LiCAM entirely. Even so, new approaches and evidence may be needed to ensure correct interpretation of cell-specific EV data.

ACKNOWLEDGEMENTS

The authors acknowledge members of the Witwer lab for helpful discussions and are grateful for support of the Department of Molecular and Comparative Pathobiology at The Johns Hopkins University. KWW is supported in part by the National Institute on Drug Abuse (NIDA; R01DA047807), the National Institute of Mental Health (NIMH; R21/R33MH118164), The National Institute of Allergy and Infectious Diseases (NIAID, R01AI144997), the National Cancer Institute (NCI) and Office of the Director (UG3CA241694), the Michael J. Fox Foundation (MJFF; Grant 09900821), and the Richman Family Precision Medicine Centre of Excellence in Alzheimer’s Disease at Johns Hopkins Medicine.

CONFLICT OF INTEREST

KWW is a member of the advisory board of NeuroDex, Inc.

ORCID

Kenneth W. Witwer https://orcid.org/0000-0003-1664-4233

REFERENCES

Altevogt, P., Ben-Ze’ev, A., Gavert, N., Schumacher, U., Schäfer, H., & Sebens, S. (2020). Recent insights into the role of LiCAM in cancer initiation and progression. International Journal of Cancer, 147(2), 3292–6. Available from: https://pubmed.ncbi.nlm.nih.gov/32588424/

Alvarez-Erviti, L., Seow, Y., Yin, H., Betts, C., Lakhal, S., & Wood, M. J. A. (2011). Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnology, 29(4), 306–9.

Anastasi, F., Masciandaro, S. M., Carratore, R. D., Dell’anno, M. T., Signore, G., Falleni, A., Middellon, L. A., & Bongioanni, P. (2021). Proteomic profiling of neuron-derived small extracellular vesicles from human plasma: Enabling single-subject analysis. International Journal of Molecular Sciences, 22(6), 1–17.

Angioli, F., Belloni, E., Giordano, M., Campioni, M., Forneris, F., Paronetto, M. P., Lupia, M., Brandas, C., Pradella, D., Di Matteo, A., Giampietro, C., Codice, G., Luise, C., Bertalot, G., Freddi, S., Mallinverno, M., Irimia, M., Moulton, J. D., Summerton, J., … Ghigna, C. (2019). A novel LiCAM isoform with angiogenic activity generated by NOVA2-mediated alternative splicing. Elife, 8, e44005. Available from: https://pubmed.ncbi.nlm.nih.gov/30829570/

Arab, T., Mallick, E. R., Huang, Y., Dong, L., Liao, Z., Zhao, Z., Gololobova, O., Smith, B., Haughey, N. J., Pienta, K. J., Slusher, B. S., Tarwater, P. M., Tosar, J. P., Zivkovic, A. M., Vreeland, W. N., Paulaitis, M. E., & Witwer, K. W. (2021). Characterization of extracellular vesicles and synthetic nanoparticles with four orthogonal single-particle analysis platforms. Journal of Extracellular vesicles, 10(6), e2079. Available from: https://pubmed.ncbi.nlm.nih.gov/33850608/

Athauda, D., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapic, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., Kapogiannis, D., & Foltynek, T. (2019). Utility of neuronal-derived exosomes to examine molecular mechanisms that affect motor function in patients with Parkinson disease: A secondary analysis for the exenatide-PD trial. JAMA Neurology, 76(4), 420–9.

Bhargava, P., Nogueras-Ortiz, C., Kim, S., Delgado-Peraza, F., Calabresi, P. A., & Kapogiannis, D. (2021). Synaptic and complement markers in extracellular vesicles in multiple sclerosis. Multiple sclerosis journal, 27(4), 509–18.

Campbell, L. A., & Mocchetti, I. (2021). Extracellular vesicles and HIV-associated neurocognitive disorders: Implications in neuropathogenesis and disease diagnosis. Neurotoxicity Research, 39(6), 2098–107. Available from: https://pubmed.ncbi.nlm.nih.gov/34618322/

Cha, D. J., Mengel, D., Mustapic, M., Liu, W., Selkoe, D. J., Kapogiannis, D., Galasko, D., Rissman, R. A., Bennett, D. A., & Walsh, D. M. (2019). miR-212 and miR-132 are downregulated in neurally derived plasma exosomes of Alzheimer's patients. Frontiers in Neuroscience, 13, 1208. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31849573

Chawla, S., Gulyani, S., Allen, R. P., Earley, C. J., Li, Xu, Van Zijl, P., & Kapogiannis, D. (2019). Extracellular vesicles reveal abnormalities in neuronal iron metabolism in restless legs syndrome. Sleep, 42(7), zs079.

Clayton, A., Boilard, E., Buzas, E. I., Cheng, L., Falcón-Perez, J. M., Gardiner, C., Gustafson, D., Gualerzi, A., Hendrix, An, Hoffman, A., Jones, J., Lászer, C., Lawson, C., Lenassi, M., Nazarenko, I., Odriscoll, L., Pink, R., Siljander, P. R.-M., Seokmadji, C., … Nieuwland, R. (2019). Considerations towards a roadmap for collection, handling and storage of blood extracellular vesicles. Journal of Extracellular Vesicles, 8(1), 1647027. Available from: https://pubmed.ncbi.nlm.nih.gov/31489143/

Clayton, A., Buschmann, D., Byrd, J. B., Carter, D. R. F., Cheng, L., Compton, C., Daaboul, G., Devitt, A., Falcon-Perez, J. M., Gardiner, C., Gustafson, D., Harrison, P., Helmbrecht, C., Hendrix, An, Hill, A., Hoffman, A., Jones, J. C., Kalluri, R., Kang, J. Y., … Nieuwland, R. (2018). Summary of the ISEV workshop on extracellular vesicles as disease biomarkers, held in Birmingham, UK, during December 2017. Journal of Extracellular Vesicles, 7(1), 1473707.

Coccozza, F., Grisard, E., Martin-Jaural, L., Mathieu, M., & Théry, C. (2020). SnapShot: Extracellular vesicles. Cell, 182(1), 262–262.e1. Available from: https://pubmed.ncbi.nlm.nih.gov/32649878/

Cuccu, E., & Meldolesi, J. (2015). Ectosomes and exosomes: Shedding the confusion between extracellular vesicles. Trends in Cell Biology, 25(6), 364–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25683921

Coleman, B. M., & Hill, A. F. (2015). Extracellular vesicles: Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases. Seminars in Cell & Developmental Biology, 40, 89–98. Available from: https://pubmed.ncbi.nlm.nih.gov/25704308/

Colombo, F., & Meldolesi, J. (2015). Li-CAM and N-CAM: From adhesion proteins to pharmacological targets. Trends in Pharmacological Sciences, 36(11), 769–81. Available from: https://pubmed.ncbi.nlm.nih.gov/26478212/

Cressatti, M., Galindez, J. M., Juwara, L., Orlovetskie, N., Velly, A. M., Eintracht, S., Liberman, A., Gornitsky, M., & Schipper, H. M. (2021). Characterization and heme oxygenase-1 content of extracellular vesicles in human biologids. Journal of Neurochemistry, 157(6), 2195–209.

Dagur, R. S., Liao, Ke, S., Niu, F., Sun, Z., Lyubchenko, Y. L., Peeples, E. S., Hu, G., & Buch, S. (2020). Neuronal-derived extracellular vesicles are enriched in the brain and serum of HIV-1 transgenic rats. Journal of Extracellular Vesicles, 9(1), 1703249. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32002168
GOMES and WITWER

Sun, B., Dalvi, P., Abadjian, L., Tang, N., & Pulliam, L. (2017). Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV. AIDS, 31(14), F9–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28692534

Sun, B., Fernandes, N., & Pulliam, L. (2019). Profile of neuronal exosomes in HIV cognitive impairment exposes sex differences. AIDS, 33(11), 1683–92.

Thérié, C., Wittwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkinson-Smith, G. K., Ayre, D. C., Bach, J.-M., Bachurski, D., Baharvand, H., Balaj, L., Baladzicino, S., Bauer, N. N., Baxter, A. A., Behawu, M., … Zuba-Surma, E. K. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. Journal of Extracellular Vesicles, 7(1), 135750. Available from: https://www.tandfonline.com/doi/full/10.1080/20013078.2018.135750

Thompson, A. G., Gray, E., Heman-Ackah, S. M., Mäger, I., Talbot, K., El Andaloussi, S., Wood, M. J., & Turner, M. R. (2016). Extracellular vesicles in neurodegenerative disease – pathogenesis to biomarkers. Nature Reviews Neuroscience, 16(6), 346–57. Available from: https://pubmed.ncbi.nlm.nih.gov/27174238/

Trnka, P., Ivanova, L., Hiatt, M. J., & Matsell, D. G. (2012). Urinary biomarkers in obstructive nephropathy. Clinical Journal of American Society of Nephrology, 7(10), 1567–75.

Upadhya, R., & Shetty, A. K. (2021). Extracellular vesicles for the diagnosis and treatment of Parkinson’s disease. Aging and Disease, 12(6), 1438–50. Available from: https://pubmed.ncbi.nlm.nih.gov/34527420/

Van Deun, J., Mestdagh, P., Agostinis, P., Akay, Ö., Anand, S., & Anckaert, J. et al. (2017). EV-TRACK: Transparent reporting and centralizing knowledge in extracellular vesicle research. Nature Methods, 14(3), 228–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28245209

Van Niel, G., & Théry, C. (2019). On primacy, precision, and popularity influencing a choice of nomenclature. Journal of Extracellular Vesicles, 8(3), 1–25. Available from: https://pubmed.ncbi.nlm.nih.gov/33473263/

Walker, K. A., Chawla, S., Nogueras-Ortiz, C., Coresh, I., Sharrett, A. R., Wong, D. F., Jack, C. R., Spychalla, A. J., Gottesman, R. F., & Kapogiannis, D. (2021). Neuronal insulin signaling and brain structure in nondemented older adults: The atherosclerosis risk in communities study. Neurobiology of Aging, 97, 65–72.

Webber, J., Stone, T. C., Katilius, E., Smith, B. C., Gordon, B., & Mason, M. D., Tabi, Z., Brewis, I. A., Clayton, A. (2014). Proteomics analysis of cancer exosomes using a novel modified aptamer-based array (somacanttm) platform. Molecular & Cellular Proteomics, 13(4), 1560–64.

Winston, C. N., Romero, H. K., Ellisman, M., Nauss, S., Julovich, D. A., Conger, T., Hall, J. R., Campana, W., O'bryant, S. E., Nievergelt, C. M., Baker, D. G., … Caputo, F., & Prina-Mello, A. (2021). Measuring particle concentration of multimodal synthetic reference materials and extracellular vesicles with orthogonal techniques: Who is up to the challenge? Journal of extracellular vesicles, 10(3). Available from: https://pubmed.ncbi.nlm.nih.gov/33473263/

Witwer, K. W., Bouras, E., Memis, E. T., Bora, A., Lääser, C., Lötjönn, J., Tho, E. N., Møller, E., Johnsen, B., Svendsen, B., … Pulliam, L. (2017). Blood neuron-derived exosomes as biomarkers of cognitive impairment to dementia with blood extracellular protein profile. Alzheimer’s Dement (Amsterdam, Netherlands), 3, 63–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27408937

Witwer, K. W., Buzás, E. I., Temburi, M. K., Patel, V. P., Lagow, E. L., Brady, O. A., Tian, J., Boulos, M. I., & Galileos, D. S. (2009). Stimulation of glioma cell motility by expression, proteolysis, and release of the IIa neural cell recognition molecule. Cancer Cell International, 9, 27. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3243858/

Yang, M., Adla, S., Temburi, M. K., Patel, V. P., Lagow, E. L., Brady, O. A., Tian, J., Boulos, M. I., & Galileos, D. S. (2011). Stimulation of human glioma cell motility correlates with FAK activation. Journal of Neuro-Oncology, 105(1), 27–44.

Yates, A. G., Pink, R. C., Erdbrügger, U., Lötjönn, P. R., Dellar, E. R., & Pantazi, P., Akbar, N., Cooke, W. R., Vatish, M., Dias-Neto, E., Anthony, D. C., Couch, Y. (2022). In sickness and in health: The functional role of extracellular vesicles in physiology and pathology in vivo: Part I: Health and Normal Physiology: Part I: Health and Normal Physiology, 11(1), e12151. Available from: https://pubmed.ncbi.nlm.nih.gov/35041249/

Yumaka, K., Takahashi, K., Usuki, S., Mikami, D., Sun, H., & Hanamatsu, H. et al. (2019). Plant sphingolipids promote extracellular vesicle release and alleviate amyloid-β pathologies in a mouse model of Alzheimer’s disease. Science Reports, 9(1).

Zhao, A., Li, Y., Yan, Y., Qiu, Y., Li, B., Xu, W., Wang, Y., Liu, J., & Deng, Y. (2020). Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer’s dementia. Translational Neurodegeneration, 9(1), 30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32741361

Zou, J., Guo, Y., Wei, L., Yu, F., Yu, Bo, & Xu, A. (2020). Long noncoding RNA POU3F3 and α-synuclein in plasma LICAM exosomes combined with β-glucocerebrosidase activity: Potential predictors of Parkinson’s disease. Neurotherapeutics, 17(3), 104–19.
SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Gomes, D. E., & Witwer, K. W. (2022). L1CAM-associated extracellular vesicles: A systematic review of nomenclature, sources, separation, and characterization. Journal of Extracellular Biology, 1, e35. https://doi.org/10.1002/jex2.35